



Piramal Life Sciences

knowledge action care

7th November, 2012

The Secretary

BSE Limited,

Corporate Relationship Dept.,

1st Floor, New Trading Wing,

Rotunda Building, P.J. Towers,

Dalal Street, Fort,

Mumbai – 400 001.

Fax No. 22723121 / 22721072 / 22722037

The Secretary

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor,

Plot No. C/1, G-Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai – 400 051.

Fax No. 26598237 / 26598238

Dear Sir,

Sub: Typographical Error - Disclosure u/r 13(6) r/w 13(3) of SEBI (Prohibition of Insider Trading) Regulations, 1992 (“SEBI Insider Trading Regulations”)

Ref: Our letter dated 1st November, 2012

Ref: SCRIP CODE: BSE: 532979 / NSE Symbol: PIRLIFE

We refer to our letter dated 1st November, 2012, wherein we submitted disclosure under Regulation 13(3) r/w 13(6) of the SEBI Insider Trading Regulations in respect of transfer of 36,00,556 equity shares (13.87% of the Total Issued Share Capital) of the Company from Paramount Pharma Private Limited to PHL Holdings Private Limited (“PHL Holdings”).

We refer to the letter dated 2nd November, 2012 of PHL Holdings, wherein the revised disclosure under reg. 13(3) submitted to the Stock Exchanges, contained a typographical error whereby the percentage of share holding prior to the acquisition mentioned in the 2nd column under heading ‘Shareholding prior to acquisition’ of Form ‘C’ was erroneously typed as “13.87%” instead of “19.21%”.

Pursuant to the requirements of regulation 13(6) of the SEBI Insider Trading Regulations, we forward herewith the revised disclosure.

Kindly acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For **Piramal Life Sciences Limited**

Ankit Sheth

Company Secretary

Encl: a/a

Piramal Life Sciences Limited

Regd. Office : Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

Secretarial Dept : Piramal Tower Annexe, 1st floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

T +91 22 3046 7839/3046 7953 F +91 22 3046 7855


W www.piramallifesciences.com

FORM 'C'
Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992
[Regulation 13(3)]

Regulation 13(3)—Details of change in shareholding in respect of persons holding more than 5% shares in a listed company - Piramal Life Sciences Limited

Name, PAN No. & address of shareholders	Share-holding prior to acquisition	No. & % of shares/ voting rights acquired	Date of acquisition	Date of intimation to company	Mode of acquisition on (market purchase/ public rights/ preferential offer etc.)	No. & % of shares/ voting rights post acquisition	Trading member through whom the trade was executed with SEBI Registration No. of the TM	Exchange on which the trade was executed	Buy quantity	Buy value	Sell quantity	Sell value
PHL Holdings Private Limited PAN NO.:AABCD3999D 8th Floor, Piramal Tower , Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013	Number of shares: 49,87,924 Percentage: 19.21%	Number of shares: 36,00,556 Percentage: 13.87%	30th October, 2012	30th October, 2012	Acquisition is pursuant to a Scheme of Amalgamation and Arrangement between BMK Laboratories Private Limited (BMK) and Cadeau Laboratories Private Limited (Cadeau) and Paramount Pharma Private Limited (Paramount) and Cavaal Fininvest Private Limited (Cavaal) and PHL Holdings Private Limited and their respective shareholders ("the Scheme") Pursuant to this Scheme, Paramount which was holding the said 36,00,556 Shares has merged with PHL Holdings Private Limited.	Number of shares: 85,88,460 Percentage: 33.08%	N.A.	N.A.	Number of shares Acquired (Pursuant to Scheme): 49,87,924	N.A.	N.A.	N.A.

For PHL Holdings Private Limited


Sunil Adulkia (Director)

CERTIFIED TRUE COPY

FOR PIRAMAL LIFE SCIENCES LIMITED



COMPANY SECRETARY